-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Article source: Medical Rubik's Cube Info
Author: Shi Bei
On December 1, Bionomics announced that the US FDA granted the company a first-in-class new oral therapy BNC210 fast track designation for the treatment of acute social anxiety disorder (SAD) and other anxiety-related diseases
Social anxiety disorder is a serious anxiety disorder characterized by persistent and intense fear of social interactions or performance-related conditions
BNC210 is an oral selective negative allosteric modulator (NAM) for α7 nicotinic acetylcholine receptor (α7 nAChR)
A previous phase IIa study of patients with generalized anxiety disorder (GAD) achieved encouraging results.
Bionomics will initiate a phase II clinical trial code-named PREVALIL at the end of 2021 to evaluate the efficacy of BNC210 as a single-dose treatment for patients with acute SAD